Cargando…

SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine-induced systemic antibody profiles are well characterized; however, little is known about whether intranasal mucosal antibodies are induced or can neutralize virus in response to mRNA vaccination. OBJECTIVE: We sou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Kevin T., Cobos-Uribe, Catalina, Knight, Noelle, Jonnalagadda, Rithika, Robinette, Carole, Jaspers, Ilona, Rebuli, Meghan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290737/ https://www.ncbi.nlm.nih.gov/pubmed/37781659 http://dx.doi.org/10.1016/j.jacig.2023.100129

Ejemplares similares

Understanding the Relationship Between Neutrophil Function and Demographic Variables
por: Hickman, Elise, et al.
Publicado: (2023)

Expanded characterization of in vitro polarized M0, M1, and M2 human monocyte-derived macrophages: Bioenergetic and secreted mediator profiles
por: Hickman, Elise, et al.
Publicado: (2023)

Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial
por: Rebuli, Meghan E., et al.
Publicado: (2021)

Smoking and e-cigarette use: key variables in testing IgA-oriented intranasal vaccines
por: McGrath, Joshua J C, et al.
Publicado: (2022)

Development of LC-HRMS Untargeted Analysis Methods for Nasal Epithelial Lining Fluid Exposomics
por: Hsiao, Yun-Chung, et al.
Publicado: (2022)

Distinguishing Human Peripheral Blood NK Cells from CD56(dim)CD16(dim)CD69(+)CD103(+) Resident Nasal Mucosal Lavage Fluid Cells
por: Rebuli, Meghan E., et al.
Publicado: (2018)

Impact of inhaled pollutants on response to viral infection in controlled exposures
por: Rebuli, Meghan E., et al.
Publicado: (2021)

The Effects of Wildfire Smoke on Asthma and Allergy
por: Noah, Terry L., et al.
Publicado: (2023)

Navigating the bridge between wet and dry lab toxicology research to address current challenges with high-dimensional data
por: Payton, Alexis, et al.
Publicado: (2023)

Broadly Neutralizing Antibodies for Influenza: Passive Immunotherapy and Intranasal Vaccination
por: Biswas, Mrityunjoy, et al.
Publicado: (2020)

Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice
por: Li, Jia-Qi, et al.
Publicado: (2021)

Systemic and Mucosal Antibody Responses to Soluble and Nanoparticle-Conjugated Antigens Administered Intranasally
por: Howe, Savannah E., et al.
Publicado: (2016)

Intranasal administration of sodium nitroprusside augments antigen-specific mucosal and systemic antibody production in mice
por: Tada, Rui, et al.
Publicado: (2023)

Potentiating Lung Mucosal Immunity Through Intranasal Vaccination
por: Nelson, Sean A., et al.
Publicado: (2021)

Diesel exposure suppresses natural killer cell function and resolution of eosinophil inflammation: a randomized controlled trial of exposure in allergic rhinitics
por: Pawlak, Erica A., et al.
Publicado: (2016)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
por: Longet, Stephanie, et al.
Publicado: (2022)

Effect of Broccoli Sprouts and Live Attenuated Influenza Virus on Peripheral Blood Natural Killer Cells: A Randomized, Double-Blind Study
por: Müller, Loretta, et al.
Publicado: (2016)

Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice
por: Hu, Mary C., et al.
Publicado: (2007)

Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies
por: Barnard, Dale, et al.
Publicado: (2007)

Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum
por: Friedman, James, et al.
Publicado: (2012)

Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
por: Halwe, Sandro, et al.
Publicado: (2021)

A Bacillus-based Coxsackie virus A16 mucosal vaccine induces strong neutralizing antibody responses
por: Cao, Yin-Guang, et al.
Publicado: (2019)

Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody
por: Cao, Xiaoling, et al.
Publicado: (2022)

Nasal biomarkers of immune function differ based on smoking and respiratory disease status
por: Rebuli, Meghan E., et al.
Publicado: (2023)

Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2
por: Nguyen, Khue G., et al.
Publicado: (2022)

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
por: Mao, Tianyang, et al.
Publicado: (2022)

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
por: Cheeseman, Hannah M., et al.
Publicado: (2016)

Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
por: Moser, Michael J., et al.
Publicado: (2023)

Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses
por: Kawagishi, Takahiro, et al.
Publicado: (2023)

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
por: Duty, J. Andrew, et al.
Publicado: (2022)

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8(+) T cell responses
por: Ishii, Hiroshi, et al.
Publicado: (2022)

Intranasal administration of a VLP‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern
por: Rothen, Dominik A., et al.
Publicado: (2022)

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
por: Hasegawa, Hideki, et al.
Publicado: (2009)

Suitability of Polymyxin B as a Mucosal Adjuvant for Intranasal Influenza and COVID-19 Vaccines
por: Yoshino, Naoto, et al.
Publicado: (2023)

Wildfire smoke exposure and early childhood respiratory health: a study of prescription claims data
por: Dhingra, Radhika, et al.
Publicado: (2023)

A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle
por: Williams, Laura B. A., et al.
Publicado: (2019)

Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120
por: Jiang, Pengfei, et al.
Publicado: (2006)

T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
por: Arunachalam, Prabhu S., et al.
Publicado: (2020)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

Intranasal administration with recombinant Bacillus subtilis induces strong mucosal immune responses against pseudorabies
por: Wang, Jialu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_13usnt3kd7j3dtfk3e3vbap5tc